![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Cue Health Receives $481 Million to Produce Point-of-Care COVID-19 Tests
Cue Health Receives $481 Million to Produce Point-of-Care COVID-19 Tests
![MoneyinAir.gif](https://www.fdanews.com/ext/resources/test/Device_Images4/MoneyinAir.gif?t=1578528099&width=430)
Cue Health has been granted $481 million from the Department of Defense to manufacture and deploy millions of units of its rapid COVID-19 test.
The point-of-care molecular test detects viral RNA using a nasal swab sample from the lower part of the nose. The contract will go toward expanding the company’s production capacity and delivering 6 million tests by March of next year.
The test, which received an FDA Emergency Use Authorization for point-of-care use, delivers results in about 20 minutes using an automated cartridge reader and a mobile health app.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct